Brodalumab
- TRADE NAME: Siliq (Valeant)
- INDICATIONS: Moderate-to-severe plaque psoriasis
- CLASS: Interleukin-17A (IL-17A) antagonist / interleukin-17 inhibitor, Monoclonal antibody
- HALF-LIFE: N/A
FDA APPROVAL DATE: 02/15/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP450 substrates, Live vaccines
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk
Contra-indicated in patients with Crohn's disease.
SUICIDAL IDEATION AND BEHAVIOR
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of brodalumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric